Considering that soluble guanylate cyclase (sGC) stimulation has been proven to exert antifibrotic properties, in very recent work from our group dermal SSc MVECs were treated with the sGC stimulator MK-2947 to unravel if this compound could modulate their angiogenic abilities and myofibroblast-like phenotype [110]. The gene discussed is SGCB; the disease is systemic sclerosis.